Will Datopotamab be reimbursed by medical insurance?

Datopotamab (Datopotamab), as a TROP2 antibody drug conjugate (ADC) that has attracted great global attention in recent years, has quickly attracted close attention from patients with advanced solid tumors after its domestic launch. In particular, its potential application scenarios in breast cancer, lung cancer and other diseases are highly anticipated. However, due to its short time on the market, the domestic medical insurance system has not yet included it in the reimbursement catalog, so it is currently in the fully self-pay stage. For high-value innovative drugs, there are often many steps to go through from listing to entering medical insurance, including real-world data accumulation, pharmacoeconomic evaluation, medical insurance negotiation cycle, etc. Therefore, it is common for dabratuzumab to not be included in medical insurance in a short period of time.

From the perspective of medical insurance policy trends, the new generation of ADC drugs tend to be cautious in entering the medical insurance catalog due to factors such as high prices, complex manufacturing processes, and expanded indications. In recent years, domestic medical insurance access has tended to cover innovative drugs with clear benefit groups, stable real-world effects, and obvious economic advantages. However, dedabrotuzumab is currently in the stage of continuous expansion of global indications and still needs to wait for more data from actual clinical use to provide a basis for future medical insurance evaluation. In addition, the urgency of medical insurance needs for different cancer types will also affect the speed of drug inclusion. For example, if there is a clear efficacy trend for refractory groups in the future, the medical insurance department may adjust the assessment direction based on policy priorities.

For people who currently need medication, not yet being covered by medical insurance means higher treatment costs, but they can also partially rely on commercial insurance, self-pay assistance channels or hospital in-hospital projects to reduce the burden. With the advancement of many key international studies, more and more countries are paying attention to the accessibility of this type of ADC drugs. Therefore, in the next 1 to 2 years, dabrotuzumab is expected to usher in policy and price updates.

Reference materials: https://www.google.com.hk/